Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH ALHALEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1700830353
CMS profile
32241
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$420.45

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $420.45 27

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH ALHALEL

NPI 1700830353 · CMS profile ID 32241

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700830353?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700830353?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700830353?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1700830353?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $420.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $24.1512/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672287 CMS
AbbVie Inc. $25.3512/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672285 CMS
AbbVie Inc. $23.4211/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672281 CMS
AbbVie Inc. $2.1611/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672283 CMS
AbbVie Inc. $15.8111/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672279 CMS
AbbVie Inc. $20.1510/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672277 CMS
Intercept Pharmaceuticals, Inc. $15.0210/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739842497 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.3109/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737481395 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.0709/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115787 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.8709/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115791 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.2609/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115781 CMS
AbbVie Inc. $19.6509/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672275 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5208/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115775 CMS
AbbVie Inc. $14.1408/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672273 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5408/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115769 CMS
AbbVie Inc. $14.1807/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672271 CMS
AbbVie Inc. $10.1106/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672269 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.2506/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737481393 CMS
Romark Laboratories, LC $16.5706/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749987725 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.7505/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737481391 CMS
AbbVie Inc. $12.2905/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721672267 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.5403/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737481389 CMS
PFIZER INC. $5.3102/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743134989 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.0602/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115765 CMS
Merck Sharp & Dohme Corporation $11.5202/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747735095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.7701/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115759 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.6801/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747115755 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $749.94 37
PY2020 $420.45 27
PY2021 $703.45 46
PY2022 $1,041.54 42
PY2023 $775.96 21
PY2024 $1,310.53 38
PY2025 $447.58 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,790.88 227
PY2024 Principal investigator $269,533.46 68
PY2023 Principal investigator $335,027.89 61
PY2022 Recipient $1.00 1
PY2022 Principal investigator $35,164.94 37
PY2021 Recipient $938.46 1
PY2021 Principal investigator $34,998.93 15
PY2020 Principal investigator $98,605.96 19
PY2019 Recipient $9,135.15 2
PY2019 Principal investigator $18,309.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311837
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304927
Principal investigator 1 Allergan, Inc. $826.50 10/19/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303499
Principal investigator 1 Allergan, Inc. $115.00 09/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721300307
Principal investigator 1 Allergan, Inc. $980.00 09/18/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298509
Principal investigator 1 Allergan, Inc. $9,597.85 07/20/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285253
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,600.00 06/02/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737082297
Principal investigator 1 Eli Lilly and Company $9,231.00 05/05/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 728732397
Principal investigator 1 Allergan, Inc. $420.00 04/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721273149
Principal investigator 1 Allergan, Inc. $10,839.50 04/20/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271185
Principal investigator 1 Allergan, Inc. $3,600.00 04/01/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721268099
Principal investigator 1 Eli Lilly and Company $56.68 03/23/2020 Non-covered Recipient Entity
RIO GRANDE GASTROENTEROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 728749331
Principal investigator 1 Allergan, Inc. $4,123.00 03/18/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265397
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262935
Principal investigator 1 PFIZER INC. $3,186.18 02/28/2020 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949010453
Principal investigator 1 PFIZER INC. $7,713.75 02/28/2020 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949010757
Principal investigator 1 Allergan, Inc. $826.50 02/17/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721257663
Principal investigator 1 PFIZER INC. $23,800.00 02/07/2020 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742878843
Principal investigator 1 Allergan, Inc. $1,235.00 01/20/2020 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248591